{
    "hands_on_practices": [
        {
            "introduction": "The first step in designing any Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) therapy is identifying a suitable target site, which is fundamentally constrained by the nuclease's requirement for a specific Protospacer Adjacent Motif (PAM). The frequency of this PAM sequence within the genome determines the targeting flexibility, and we can estimate this using basic probability. This foundational exercise  provides a quantitative basis for comparing different CRISPR nucleases, demonstrating how a subtle difference in the PAM sequence dramatically alters the therapeutic potential of a tool.",
            "id": "5086825",
            "problem": "A gene therapy team is evaluating locus coverage for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems in a large eukaryotic genome. They model the genome as a random deoxyribonucleic acid (DNA) sequence in which each nucleotide base ($\\text{A}$, $\\text{C}$, $\\text{G}$, $\\text{T}$) occurs independently with equal probability $1/4$ at each position. They consider $20$ base pair ($20$ bp) target sites that must be immediately flanked on the required side by a Protospacer Adjacent Motif (PAM) in order to be editable.\n\nTwo nucleases are considered:\n- Streptococcus pyogenes Cas9 (SpCas9), which requires a $3'$ PAM of $\\,\\text{NGG}\\,$ adjacent to the $20$ bp target on the non-target strand.\n- Staphylococcus aureus Cas9 (SaCas9), which requires a $5'$ PAM of $\\,\\text{NNGRRT}\\,$ adjacent to the $20$ bp target on the non-target strand, where $\\text{R}$ denotes any purine ($\\text{A}$ or $\\text{G}$).\n\nUsing only the random DNA model and the independence of bases, derive the expected fraction (as a decimal or exact fraction) of $20$ bp targets that are properly flanked by $\\,\\text{NGG}\\,$ and by $\\,\\text{NNGRRT}\\,$, respectively, and then compute the ratio $\\rho$ of SpCas9 PAM availability to SaCas9 PAM availability,\n$$\n\\rho \\equiv \\frac{\\text{fraction of $20$ bp targets flanked by }\\text{NGG}}{\\text{fraction of $20$ bp targets flanked by }\\text{NNGRRT}}.\n$$\nFinally, interpret how the value of $\\rho$ affects therapeutic locus coverage under this model. Report only the numerical value of $\\rho$ as your final answer. If you choose a decimal, use an exact value rather than a rounded approximation.",
            "solution": "The problem is evaluated to be scientifically grounded, well-posed, objective, and internally consistent. It is based on established principles of molecular biology and probability theory, using a standard simplified model for estimating CRISPR-Cas target site frequency. All necessary information is provided, and the terms are defined unambiguously. Therefore, a solution will be derived.\n\nThe problem asks for the ratio of the availability of Protospacer Adjacent Motifs (PAMs) for two different Cas nucleases, $\\text{SpCas9}$ and $\\text{SaCas9}$, within a random deoxyribonucleic acid (DNA) sequence model.\n\nFirst, we establish the fundamental probabilities based on the problem statement. The genome is modeled as a random sequence where each nucleotide base—adenine ($\\text{A}$), cytosine ($\\text{C}$), guanine ($\\text{G}$), and thymine ($\\text{T}$)—occurs independently with an equal probability of $\\frac{1}{4}$.\n$$P(\\text{A}) = P(\\text{C}) = P(\\text{G}) = P(\\text{T}) = \\frac{1}{4}$$\n\nWe need to calculate the probability of occurrence for each specific PAM sequence. The probability of a sequence is the product of the probabilities of its constituent bases, due to the assumption of independence. We must first define the probabilities for the IUPAC nucleotide ambiguity codes used in the PAM definitions.\nThe code $\\text{N}$ represents any of the four bases ($\\text{A}$, $\\text{C}$, $\\text{G}$, or $\\text{T}$). Its probability is:\n$$P(\\text{N}) = P(\\text{A}) + P(\\text{C}) + P(\\text{G}) + P(\\text{T}) = \\frac{1}{4} + \\frac{1}{4} + \\frac{1}{4} + \\frac{1}{4} = 1$$\nThe code $\\text{R}$ represents a purine, which is either adenine ($\\text{A}$) or guanine ($\\text{G}$). Its probability is:\n$$P(\\text{R}) = P(\\text{A}) + P(\\text{G}) = \\frac{1}{4} + \\frac{1}{4} = \\frac{1}{2}$$\n\nNow, we can calculate the probability of finding each PAM at any given location. This probability is equivalent to the expected fraction of $20$ bp targets that are properly flanked by the respective PAM.\n\nFor $\\text{Streptococcus pyogenes}$ Cas9 ($\\text{SpCas9}$), the required PAM is $\\text{NGG}$. The length of this PAM is $3$ bases. The probability of this sequence, which we denote $f_{\\text{SpCas9}}$, is:\n$$f_{\\text{SpCas9}} = P(\\text{NGG}) = P(\\text{N}) \\times P(\\text{G}) \\times P(\\text{G})$$\nSubstituting the probabilities:\n$$f_{\\text{SpCas9}} = 1 \\times \\frac{1}{4} \\times \\frac{1}{4} = \\frac{1}{16}$$\n\nFor $\\text{Staphylococcus aureus}$ Cas9 ($\\text{SaCas9}$), the required PAM is $\\text{NNGRRT}$. The length of this PAM is $6$ bases. The probability of this sequence, which we denote $f_{\\text{SaCas9}}$, is:\n$$f_{\\text{SaCas9}} = P(\\text{NNGRRT}) = P(\\text{N}) \\times P(\\text{N}) \\times P(\\text{G}) \\times P(\\text{R}) \\times P(\\text{R}) \\times P(\\text{T})$$\nSubstituting the probabilities:\n$$f_{\\text{SaCas9}} = 1 \\times 1 \\times \\frac{1}{4} \\times \\frac{1}{2} \\times \\frac{1}{2} \\times \\frac{1}{4} = \\frac{1}{4 \\times 2 \\times 2 \\times 4} = \\frac{1}{64}$$\n\nThe problem defines the ratio $\\rho$ as the fraction of targets flanked by $\\text{NGG}$ divided by the fraction of targets flanked by $\\text{NNGRRT}$.\n$$\\rho = \\frac{f_{\\text{SpCas9}}}{f_{\\text{SaCas9}}}$$\nSubstituting the calculated fractions:\n$$\\rho = \\frac{\\frac{1}{16}}{\\frac{1}{64}} = \\frac{1}{16} \\times \\frac{64}{1} = \\frac{64}{16} = 4$$\n\nThe numerical value of the ratio $\\rho$ is $4$.\n\nFinally, we interpret the meaning of this value. A ratio of $\\rho=4$ signifies that, under the specified random DNA model, a potential target site for $\\text{SpCas9}$ (requiring an $\\text{NGG}$ PAM) is four times more common than a potential target site for $\\text{SaCas9}$ (requiring an $\\text{NNGRRT}$ PAM). In the context of therapeutic genome editing, this means that $\\text{SpCas9}$ offers a significantly higher \"targeting density\" or \"locus coverage\". For any given region of the genome where an edit is desired, there are, on average, four times as many available sites for $\\text{SpCas9}$ as there are for $\\text{SaCas9}$. This greater availability of target sites increases the flexibility for designing a therapeutic strategy, making it more likely that an optimal guide RNA can be designed to direct the nuclease to a position that is both effective for gene correction and has minimal off-target potential. Conversely, the sparser targeting of $\\text{SaCas9}$ may limit its applicability if no suitable PAM is located near the desired genomic locus.",
            "answer": "$$\\boxed{4}$$"
        },
        {
            "introduction": "After selecting a nuclease and target, the complete editing system must be delivered into the target cells, a task often accomplished using viral vectors like Adeno-Associated Virus (AAV). However, physical constraints, such as the limited DNA packaging capacity of AAVs, impose strict design limitations. This practice problem  presents a real-world engineering challenge faced by gene therapy developers, forcing you to calculate genetic payloads and evaluate clever solutions like using smaller nuclease orthologs or splitting the components across multiple vectors.",
            "id": "5086866",
            "problem": "A clinical gene therapy program aims to correct a single-nucleotide pathogenic variant in hepatocytes via Homology-Directed Repair (HDR) using a clustered regularly interspaced short palindromic repeats (CRISPR) nuclease. The team plans to deliver the genome editing system with Adeno-Associated Virus (AAV). The following facts are known and widely accepted:\n\n- Adeno-Associated Virus (AAV) has an effective packaging capacity near $4.7\\ \\mathrm{kb}$ for the DNA cargo between inverted terminal repeats.\n- According to the Central Dogma of Molecular Biology, a protein of $n$ amino acids is encoded by an open reading frame of approximately $3n$ base pairs, plus a $3$ base pair stop codon.\n- Streptococcus pyogenes Cas9 (SpCas9) is $1368$ amino acids, and Staphylococcus aureus Cas9 (SaCas9) is $1053$ amino acids.\n- The clinical edit requires a single guide RNA (sgRNA) expression cassette (U6 promoter and scaffold) of $0.35\\ \\mathrm{kb}$ and a donor DNA template with homology arms totaling $1.5\\ \\mathrm{kb}$.\n- The intended Cas9 expression uses a compact promoter of $0.6\\ \\mathrm{kb}$ and a polyadenylation signal of $0.2\\ \\mathrm{kb}$.\n\nUsing these foundational facts, first compute the approximate DNA length of the SpCas9 coding sequence and the SaCas9 coding sequence. Then, assess whether a single AAV vector can carry SpCas9 plus the sgRNA cassette plus the donor template together with the indicated promoter and polyadenylation signal without exceeding the packaging limit. If the required payload exceeds capacity, evaluate the practicality of alternative delivery strategies that are scientifically grounded in AAV vector design and protein reconstitution.\n\nWhich option(s) correctly reflect the capacity calculation and propose viable strategy(ies) when over capacity?\n\nA. A single AAV can carry SpCas9, the sgRNA cassette, the $0.6\\ \\mathrm{kb}$ promoter, the $0.2\\ \\mathrm{kb}$ polyadenylation signal, and the $1.5\\ \\mathrm{kb}$ donor template without exceeding $4.7\\ \\mathrm{kb}$.\n\nB. Use split-intein SpCas9 delivered via two AAVs: package the N-terminal fragment of SpCas9 with the sgRNA cassette under one promoter and polyadenylation signal in one vector, and the C-terminal fragment of SpCas9 with the donor template under a promoter and polyadenylation signal in the other; the intein-mediated protein splicing reconstitutes full-length Cas9 in co-transduced cells.\n\nC. Use a dual-AAV strategy with SaCas9: package SaCas9 with the $0.6\\ \\mathrm{kb}$ promoter, $0.2\\ \\mathrm{kb}$ polyadenylation signal, and the $0.35\\ \\mathrm{kb}$ sgRNA cassette in one vector, and the $1.5\\ \\mathrm{kb}$ donor template in a second vector; co-transduction enables HDR.\n\nD. Engineer a single AAV to carry an oversized genome $>6.5\\ \\mathrm{kb}$; despite exceeding the nominal capacity, stable packaging and full-length genomes are routinely achieved, making this a practical solution.\n\nE. Replace SpCas9 with SaCas9 and still use a single AAV to carry SaCas9 plus the $0.6\\ \\mathrm{kb}$ promoter, $0.2\\ \\mathrm{kb}$ polyadenylation signal, the $0.35\\ \\mathrm{kb}$ sgRNA cassette, and the $1.5\\ \\mathrm{kb}$ donor template; this fits under $4.7\\ \\mathrm{kb}$.",
            "solution": "The problem statement is evaluated for validity.\n\n**Step 1: Extract Givens**\n-   AAV packaging capacity: near $4.7\\ \\mathrm{kb}$.\n-   Protein to DNA length conversion: A protein of $n$ amino acids is encoded by an open reading frame of approximately $3n$ base pairs, plus a $3$ base pair stop codon.\n-   *Streptococcus pyogenes* Cas9 (SpCas9) length: $1368$ amino acids.\n-   *Staphylococcus aureus* Cas9 (SaCas9) length: $1053$ amino acids.\n-   Single guide RNA (sgRNA) expression cassette size: $0.35\\ \\mathrm{kb}$.\n-   Donor DNA template size (with homology arms): $1.5\\ \\mathrm{kb}$.\n-   Cas9 expression promoter size: $0.6\\ \\mathrm{kb}$.\n-   Cas9 expression polyadenylation signal size: $0.2\\ \\mathrm{kb}$.\n\n**Step 2: Validate Using Extracted Givens**\n-   **Scientifically Grounded**: The premises are based on fundamental principles of molecular biology (Central Dogma, genetic code) and established facts in the field of gene therapy. The AAV packaging capacity of $\\sim 4.7\\ \\mathrm{kb}$ is the canonical value. The sizes of SpCas9 and SaCas9 are correct. The sizes of the non-coding elements (promoter, polyA, sgRNA cassette, donor template) are realistic for AAV-based systems.\n-   **Well-Posed**: The problem is clearly defined. It requires calculation based on the provided data and then an evaluation of proposed strategies against the calculated constraints. A unique solution can be derived.\n-   **Objective**: The language is precise and free of subjective claims. All data are presented as objective facts.\n\n**Step 3: Verdict and Action**\nThe problem is valid. It is scientifically sound, well-posed, objective, and contains all necessary information to proceed to a solution.\n\n**Solution Derivation**\n\nFirst, we compute the DNA length of the coding sequences (CDS) for SpCas9 and SaCas9. The formula provided is:\nLength (bp) $= 3 \\times (\\text{number of amino acids}) + 3$\nLength (kb) $= (3n + 3) / 1000$\n\n**SpCas9 CDS Length:**\n-   Number of amino acids, $n_{Sp} = 1368$.\n-   Length (bp) $= 3 \\times 1368 + 3 = 4104 + 3 = 4107\\ \\mathrm{bp}$.\n-   Length (kb) $= 4.107\\ \\mathrm{kb}$.\n\n**SaCas9 CDS Length:**\n-   Number of amino acids, $n_{Sa} = 1053$.\n-   Length (bp) $= 3 \\times 1053 + 3 = 3159 + 3 = 3162\\ \\mathrm{bp}$.\n-   Length (kb) $= 3.162\\ \\mathrm{kb}$.\n\nNext, we assess whether a single AAV vector can carry all the necessary components for HDR using SpCas9. This \"all-in-one\" vector must contain the SpCas9 expression cassette, the sgRNA expression cassette, and the donor template.\n\n**Total payload for a single AAV with SpCas9:**\n-   Promoter: $0.6\\ \\mathrm{kb}$\n-   SpCas9 CDS: $4.107\\ \\mathrm{kb}$\n-   Polyadenylation signal: $0.2\\ \\mathrm{kb}$\n-   sgRNA cassette: $0.35\\ \\mathrm{kb}$\n-   Donor template: $1.5\\ \\mathrm{kb}$\n\nTotal size $= 0.6 + 4.107 + 0.2 + 0.35 + 1.5 = 6.757\\ \\mathrm{kb}$.\n\nThis total payload of $6.757\\ \\mathrm{kb}$ significantly exceeds the AAV packaging capacity of $4.7\\ \\mathrm{kb}$. Therefore, a single AAV vector strategy with SpCas9 and all components is not feasible. We must evaluate alternative strategies.\n\n**Option-by-Option Analysis**\n\n**A. A single AAV can carry SpCas9, the sgRNA cassette, the $0.6\\ \\mathrm{kb}$ promoter, the $0.2\\ \\mathrm{kb}$ polyadenylation signal, and the $1.5\\ \\mathrm{kb}$ donor template without exceeding $4.7\\ \\mathrm{kb}$.**\nAs calculated above, the total size of these components is $6.757\\ \\mathrm{kb}$. Since $6.757\\ \\mathrm{kb} > 4.7\\ \\mathrm{kb}$, this statement is factually incorrect.\n**Verdict: Incorrect.**\n\n**B. Use split-intein SpCas9 delivered via two AAVs: package the N-terminal fragment of SpCas9 with the sgRNA cassette under one promoter and polyadenylation signal in one vector, and the C-terminal fragment of SpCas9 with the donor template under a promoter and polyadenylation signal in the other; the intein-mediated protein splicing reconstitutes full-length Cas9 in co-transduced cells.**\nThis describes a standard and scientifically validated method to overcome the AAV packaging limit. SpCas9 is split into two halves, each fused to a component of a split intein. The two resulting expression cassettes are packaged into separate AAVs. Upon co-transduction of a cell, the two protein fragments are expressed and the inteins catalyze protein splicing, reconstituting a full-length, active SpCas9 protein. Let's check the cargo size for each vector. A split is typically made around amino acid $500-700$. Let's assume a split creating two fragments of roughly $2.05\\ \\mathrm{kb}$ each (half of $4.107\\ \\mathrm{kb}$), plus the small coding sequence for the inteins.\n-   **Vector 1 payload (approximate):** Promoter ($0.6\\ \\mathrm{kb}$) + N-SpCas9-Intein CDS ($\\sim 2.1\\ \\mathrm{kb}$) + PolyA ($0.2\\ \\mathrm{kb}$) + sgRNA cassette ($0.35\\ \\mathrm{kb}$) = $\\sim 3.25\\ \\mathrm{kb}$. This is well within the $4.7\\ \\mathrm{kb}$ limit.\n-   **Vector 2 payload (approximate):** Promoter ($0.6\\ \\mathrm{kb}$) + C-SpCas9-Intein CDS ($\\sim 2.1\\ \\mathrm{kb}$) + PolyA ($0.2\\ \\mathrm{kb}$) + Donor template ($1.5\\ \\mathrm{kb}$) = $\\sim 4.4\\ \\mathrm{kb}$. This is also within the $4.7\\ \\mathrm{kb}$ limit.\nThe proposed strategy is both scientifically sound and practical for packaging.\n**Verdict: Correct.**\n\n**C. Use a dual-AAV strategy with SaCas9: package SaCas9 with the $0.6\\ \\mathrm{kb}$ promoter, $0.2\\ \\mathrm{kb}$ polyadenylation signal, and the $0.35\\ \\mathrm{kb}$ sgRNA cassette in one vector, and the $1.5\\ \\mathrm{kb}$ donor template in a second vector; co-transduction enables HDR.**\nThis strategy uses the smaller SaCas9 and splits the nuclease/sgRNA from the donor template into two separate vectors.\n-   **Vector 1 (Nuclease/sgRNA) payload:** Promoter ($0.6\\ \\mathrm{kb}$) + SaCas9 CDS ($3.162\\ \\mathrm{kb}$) + PolyA ($0.2\\ \\mathrm{kb}$) + sgRNA cassette ($0.35\\ \\mathrm{kb}$) = $4.312\\ \\mathrm{kb}$. This fits within the $4.7\\ \\mathrm{kb}$ AAV capacity.\n-   **Vector 2 (Donor) payload:** The donor template itself is $1.5\\ \\mathrm{kb}$, which is easily packaged into a separate AAV vector.\nThis dual-vector approach is a very common and effective strategy for in vivo HDR-based genome editing. Co-delivering the components to the same cell allows for the desired repair.\n**Verdict: Correct.**\n\n**D. Engineer a single AAV to carry an oversized genome $>6.5\\ \\mathrm{kb}$; despite exceeding the nominal capacity, stable packaging and full-length genomes are routinely achieved, making this a practical solution.**\nThis statement is scientifically unsound in a clinical context. While some experimental studies have explored packaging genomes slightly larger than $4.7\\ \\mathrm{kb}$, the efficiency of packaging drops precipitously, and the integrity of the packaged genome is compromised (i.e., fragments are packaged). A payload of $>6.5\\ \\mathrm{kb}$ is far beyond what can be reliably packaged into a single AAV capsid. It is not \"routinely achieved\" and is certainly not considered a \"practical solution\" for clinical applications, which demand high efficiency and product consistency.\n**Verdict: Incorrect.**\n\n**E. Replace SpCas9 with SaCas9 and still use a single AAV to carry SaCas9 plus the $0.6\\ \\mathrm{kb}$ promoter, $0.2\\ \\mathrm{kb}$ polyadenylation signal, the $0.35\\ \\mathrm{kb}$ sgRNA cassette, and the $1.5\\ \\mathrm{kb}$ donor template; this fits under $4.7\\ \\mathrm{kb}$.**\nThis proposes an \"all-in-one\" vector using the smaller SaCas9. Let's calculate the total payload size.\n-   Promoter: $0.6\\ \\mathrm{kb}$\n-   SaCas9 CDS: $3.162\\ \\mathrm{kb}$\n-   Polyadenylation signal: $0.2\\ \\mathrm{kb}$\n-   sgRNA cassette: $0.35\\ \\mathrm{kb}$\n-   Donor template: $1.5\\ \\mathrm{kb}$\n\nTotal size $= 0.6 + 3.162 + 0.2 + 0.35 + 1.5 = 5.812\\ \\mathrm{kb}$.\n\nThis total payload of $5.812\\ \\mathrm{kb}$ still exceeds the AAV packaging capacity of $4.7\\ \\mathrm{kb}$. The statement that this would fit is false.\n**Verdict: Incorrect.**",
            "answer": "$$\\boxed{\\text{B, C}}$$"
        },
        {
            "introduction": "The frontier of genome editing has advanced from simply cutting DNA to making precise, single-base changes using sophisticated tools called base editors. While these editors offer incredible precision, they introduce a unique set of safety considerations. Base editors operate within a defined \"activity window,\" and any susceptible nucleotide within that window can be modified, potentially leading to unintended \"bystander\" edits alongside the desired correction. This problem  explores the critical concept of editing purity by modeling the probabilistic nature of bystander mutations, teaching you to think critically about the precision and safety of next-generation editing therapies.",
            "id": "5086894",
            "problem": "A therapeutic program employs a Cytosine Base Editor (CBE), consisting of a cytidine deaminase fused to a nuclease-deficient or nickase variant of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated protein $9$ (CRISPR-Cas9), to correct a pathogenic single-nucleotide variant in a gene expressed in human hepatocytes. The CBE binds a target site adjacent to a Protospacer Adjacent Motif (PAM) and transiently creates a single-stranded DNA (ssDNA) region within a ribonucleoprotein-induced R-loop. Within this ssDNA, the deaminase catalyzes $\\text{C}\\to \\text{U}$ deamination at cytidines located in an enzyme-dependent activity window. In most implementations, Uracil Glycosylase Inhibitor (UGI) is present to suppress the removal of uracil by Base Excision Repair (BER), and nicking biases Mismatch Repair (MMR) to resolve $\\text{U}:\\text{G}$ mismatches into $\\text{T}:\\text{A}$. This framework can generate desired edits at the target cytidine but also bystander edits at nearby cytidines within the deamination window.\n\nUsing as fundamental bases the Central Dogma (DNA encodes information through base pairing, replication maintains genotype), canonical Watson–Crick pairing, and standard probability laws (independence, conditional probability, and the law of total probability), explain mechanistically why bystander edits arise within the CBE deamination window. Then, consider a specific target site whose activity window contains exactly two ($2$) cytidines, labeled site $1$ and site $2$. Assume the following:\n- Each cytidine is deaminated with equal probability $p$ per editing attempt.\n- Conditional on deamination at a site, downstream repair independently resolves that site to a permanent $\\text{C}\\to \\text{T}$ substitution with probability $q$, and otherwise restores it to $\\text{C}$ with probability $1-q$.\n- Deamination and repair outcomes are independent between the two sites.\n\nDerive the expected haplotype frequency vector for the four possible post-editing outcomes at the two sites: $(\\text{C},\\text{C})$, $(\\text{T},\\text{C})$, $(\\text{C},\\text{T})$, and $(\\text{T},\\text{T})$, expressed in terms of $p$ and $q$. Provide your final answer as a row vector $(P_{CC},\\,P_{TC},\\,P_{CT},\\,P_{TT})$ in closed form. No numerical rounding is required, and no physical units apply. Express any probabilities as exact algebraic expressions in $p$ and $q$ using standard mathematical notation.",
            "solution": "The mechanistic origin of bystander edits within a Cytosine Base Editor (CBE) deamination window follows from widely established molecular principles. CRISPR-associated protein $9$ (Cas9) guided by a single guide RNA recognizes a target sequence adjacent to a Protospacer Adjacent Motif (PAM) and forms an R-loop that exposes a portion of the non-complementary DNA strand as single-stranded DNA (ssDNA). The fused cytidine deaminase accesses this ssDNA and catalyzes hydrolytic deamination of cytidine to uracil, converting a $\\text{C}:\\text{G}$ base pair locally to a $\\text{U}:\\text{G}$ mismatch. Because the deaminase recognizes ssDNA within a positional activity window determined by enzyme structure, dwell time, and DNA-protein geometry, any cytidine within that window can be deaminated, not solely the intended target cytidine. This positional accessibility results in bystander edits when multiple cytidines reside within the window. Uracil Glycosylase Inhibitor (UGI) limits base excision by Uracil-DNA Glycosylase, increasing the persistence of $\\text{U}$ and favoring resolution by Mismatch Repair (MMR) in a manner biased by nicking on the opposite strand toward a $\\text{T}:\\text{A}$ outcome. Thus, given multiple cytidines in the window, the same biochemical machinery can convert each accessible $\\text{C}$ to $\\text{U}$ independently, producing bystander edits at positions that are not the primary target.\n\nWe now derive haplotype frequencies using foundational probability rules. Label the two cytidines as site $1$ and site $2$. For each site, define the following events:\n- Deamination at the site occurs with probability $p$.\n- Conditional on deamination, repair resolves to a permanent $\\text{C}\\to \\text{T}$ substitution with probability $q$, and otherwise returns to $\\text{C}$ with probability $1-q$.\n\nFirst, compute the marginal probability that a single site ends as $\\text{T}$ after the full edit-and-repair process. Using conditional probability,\n$$\nP(\\text{T at a site}) \\;=\\; P(\\text{deamination}) \\times P(\\text{T} \\mid \\text{deamination}) \\;=\\; p \\times q \\;=\\; p q.\n$$\nBy the law of total probability, the complementary outcome at that site is $\\text{C}$ if either deamination did not occur or deamination occurred but repair returned the base to $\\text{C}$. Therefore,\n$$\nP(\\text{C at a site}) \\;=\\; P(\\text{no deamination}) + P(\\text{deamination}) \\times P(\\text{C} \\mid \\text{deamination})\n\\;=\\; (1-p) + p(1-q)\n\\;=\\; 1 - p q.\n$$\nUnder the assumption of independence between sites for both deamination and repair outcomes, the joint haplotype probabilities factor as products of the single-site probabilities. Let $f_{\\text{T}} = p q$ and $f_{\\text{C}} = 1 - p q$ denote the final probabilities for a single site to be $\\text{T}$ or $\\text{C}$, respectively. Then:\n- The haplotype $(\\text{C},\\text{C})$ occurs with probability\n$$\nP_{CC} \\;=\\; f_{\\text{C}} \\times f_{\\text{C}} \\;=\\; (1 - p q)^{2}.\n$$\n- The haplotype $(\\text{T},\\text{C})$ occurs with probability\n$$\nP_{TC} \\;=\\; f_{\\text{T}} \\times f_{\\text{C}} \\;=\\; (p q)(1 - p q).\n$$\n- The haplotype $(\\text{C},\\text{T})$ occurs with probability\n$$\nP_{CT} \\;=\\; f_{\\text{C}} \\times f_{\\text{T}} \\;=\\; (1 - p q)(p q).\n$$\n- The haplotype $(\\text{T},\\text{T})$ occurs with probability\n$$\nP_{TT} \\;=\\; f_{\\text{T}} \\times f_{\\text{T}} \\;=\\; (p q)^{2}.\n$$\n\nThese four outcomes exhaust all possibilities and sum to unity, which can be verified:\n$$\nP_{CC} + P_{TC} + P_{CT} + P_{TT}\n= (1 - p q)^{2} + 2(p q)(1 - p q) + (p q)^{2}\n= \\left[(1 - p q) + (p q)\\right]^{2}\n= 1^{2}\n= 1.\n$$\n\nTherefore, the expected haplotype frequency vector expressed in terms of $p$ and $q$ is\n$$\n\\left(P_{CC},\\,P_{TC},\\,P_{CT},\\,P_{TT}\\right)\n= \\left((1 - p q)^{2},\\, (p q)(1 - p q),\\, (1 - p q)(p q),\\, (p q)^{2}\\right).\n$$",
            "answer": "$$\\boxed{\\begin{pmatrix}\n(1 - p q)^{2} & (p q)(1 - p q) & (1 - p q)(p q) & (p q)^{2}\n\\end{pmatrix}}$$"
        }
    ]
}